Please login to the form below

Not currently logged in
Email:
Password:

Polleo Pharma co-founders join Chronos Therapeutics

Dr Fraser Murray and Dr Timonthy Schulz-Utermoehl become pre-clinical development VPs

Chronos Dr Fraser MurrayOxford, UK-based Chronos Therapeutics has appointed Dr Fraser Murray and Dr Timothy Schulz-Utermoehl as vice presidents of pre-clinical development.

Together, they will oversee three pre-clinical research programmes recently acquired by the privately-held biotech, which target fatigue in multiple sclerosis, addictive behaviours and post-traumatic stress disorder, respectively.

Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.

Prior to co-founding Polleo Pharma in 2014, Dr Murray served as senior director and head of discovery biology for Shire Specialty Pharmaceuticals, with a focus on central nervous system and gastrointestinal disorders.

He has also held a number of leadership roles at AstraZeneca, Calcico Therapeutics and Merck & Co.

Chronos Dr Timothy Schulz-UtermoehlMeanwhile, Dr Schulz-Utermoehl (pictured left) brings 17 years of early- and late-stage discovery research and preclinical development expertise to Chronos.

As well as co-founding Polleo Pharma alongside Dr Murray, he has worked at AstraZeneca, Merck & Co, Novo Nordisk and, most recently, Shire, where he served as a director in its exploratory projects department in the UK.

Chief executive officer of Chronos Dr Huw Jones said: “We are delighted to welcome Fraser and Timothy to Chronos at a time of significant expansion of our research portfolio.

“They bring substantial pre-clinical development expertise to our organisation and are synergistic to our recent acquisition.
“In particular, their experience as co-founders of Polleo will be invaluable as we advance our behavioural brain disease portfolio.”

4th August 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics